Friday, 16 October 2026European Markets

ARRIBATEC GROUP Stock Is 15% Up So Far Today

Loading stream...

(VIANEWS) - Shares of ARRIBATEC GROUP (Oslo Børs Benchmark Index_GI: ARR.OL) rose by a staggering 15% to kr4.60 at 11:24 EST on Monday, after two sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI is jumping 0.15% to kr1,214.99, following the last session's upward trend. This seems, up until now, a somewhat positive trend exchanging session today.

About ARRIBATEC GROUP

Arribatec Group ASA, a software and consulting company, provides digital business solutions in Norway, Europe, the Americas, and internationally. The company offers solutions for businesses, including ERP systems, integrations, consulting, health checks, develops, HR and payroll, financial and project planning, bank solutions, and travel and expenses. Its solutions include QualiWare, a management system that structures and visualizes processes, activities, regulations, and requirements; Unit4 solutions; RamBase, an ERP business solution that gives control over the value chain; Power BI solutions; Hypergene, a business management tool; Adra Suite that integrates with other financial systems; Microsoft 365; CatalystOne; and Pagero that ensures compliance with legal and electronic billing requirements. The company was incorporated in 1998 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ARRIBATEC GROUP has a trailing twelve months EPS of kr-1.37.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ARRIBATEC GROUP's stock is considered to be oversold (<=20).

Volatility

ARRIBATEC GROUP's last week, last month's, and last quarter's current intraday variation average was 3.22%, 0.63%, and 2.96%.

ARRIBATEC GROUP's highest amplitude of average volatility was 3.61% (last week), 2.51% (last month), and 2.96% (last quarter).

Volume

Today's last reported volume for ARRIBATEC GROUP is 267071 which is 115.15% above its average volume of 124131.

More news about ARRIBATEC GROUP (ARR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com